Company: VERA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-314244
Chunk: 54

Company: Vera Therapeutics, Inc.
Filing Date: 2025-12-10
Form: 424B5
Chunk 54
---
 our product candidates, including additional 
 indications that we may pursue;                                                                                 |

| • |     | existing regulations and regulatory developments in the United States and other jurisdictions; |

| • |     | our potential and ability to successfully manufacture and supply our product candidates for clinical trials and 
 for commercial use, if approved;                                                                                |

| • |     | the rate and degree of market acceptance of our product candidates, as well as the pricing and reimbursement of 
 our product candidates, if approved;                                                                            |

| • |     | our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for 
 the manufacture of our product candidates;                                                                       |

| • |     | our plans and ability to obtain and protect intellectual property rights; |

| • |     | the scope of protection we are able to establish and maintain for intellectual property rights, including 
 atacicept, MAU868 and any other product candidates we may develop;                                        |

| • |     | our ability to retain the continued service of our key personnel and to identify, hire, and then retain 
 additional qualified personnel; and                                                                     |

| • |     | our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS 
 Act and as a smaller reporting company under the Exchange Act.                                                  |

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for our management to predict all risk factors and uncertainties. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained or incorporated by reference herein, whether as a result of any new information, future events, changed circumstances or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See the section titled “Where You Can Find Additional Information” in this prospectus. 9

USE OF PROCEEDS

We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described in any prospectus
supplement